Articles tagged with Inhibitory Effects
Scientists have discovered a natural compound called sulfuretin that can halt the progression of certain forms of cancer and demyelinating conditions like multiple sclerosis. The study found that sulfuretin blocks the activity of an enzyme involved in these diseases, suggesting its potential as a treatment.
Researchers found that WNTinib significantly delayed tumour growth and extended survival in mice with hepatoblastoma cells harboring CTNNB1 mutations. The treatment also showed promise in shrinking tumors in patients' tumor tissue models, with some tumors disappearing completely.
Researchers found that female mouse models of Rett syndrome have a mosaic-like distribution of cells expressing wild-type and mutant MeCP2 protein, leading to dysregulated genes. The study also discovered an unusual disease progression, with females having more dysregulated genes at the pre-symptomatic stage than later on.
Researchers at Weill Cornell Medicine have developed a virtual screening approach to identify small molecule drug candidates targeting cancer checkpoints. The method successfully identified two compounds with potential therapeutic activity against TIM-3 and VISTA inhibitory checkpoints.
A study by Johns Hopkins Medicine found distinct immune 'signatures' in patients who developed adverse events while taking immunotherapy. These signatures, including increases in white blood cells known as Th2 and Th17, predict the development of immune-related adverse events and may be targeted for treatment.
A study from Goethe University Frankfurt reveals that venomous crustaceans, specifically remipede crabs in Mexican cenote caves, contain a variety of toxins with pharmacological potential. The xibalbines peptides effectively inhibit potassium channels and activate signaling pathways involved in pain sensitization.
Researchers found that zinc supplements can inhibit the transfer of AMR plasmids, reducing the spread of antibiotic-resistant infections. The study provides hope for developing an inexpensive and effective method to combat the growing threat of antimicrobial resistance.
Researchers at University of Gothenburg propose inhibiting somatostatin to restore glucagon release and prevent dangerous blood sugar levels. This approach has the potential to save lives and is supported by experimental results in mice with type 1 diabetes.
A phase 1b/2 clinical trial found a combination of immunotherapy and FGFR inhibitor to be safe and tolerable in patients with locally advanced or metastatic bladder cancer. The treatment showed increased response rates, including 54% for patients with high FGFR mRNA expression.
New study finds that extended estrogen suppression using aromatase inhibitors for hormone receptor-positive postmenopausal breast cancer is safe and does not increase the risk of coronary artery calcification. The duration of treatment and presence of osteoporosis were not associated with increased coronary artery calcification scores.
The CheckMate 067 trial showed that combining nivolumab and ipilimumab improved outcomes for metastatic melanoma patients, with a median survival time over six years. Long-term follow-up found no new safety signals for the treatment, and metastatic melanoma survivors become increasingly likely to die of other causes as they age.
Researchers tested tivozanib with nivolumab in patients with advanced clear cell renal cell carcinoma and found no benefit from combining the two treatments. Repeat ICI therapy should be discouraged due to lack of improvement in overall survival or response rates.
Researchers at Flinders University and University of South Australia have discovered a potential breakthrough in treating the most aggressive forms of prostate cancer using CDKI-73, a novel drug inhibitor. The study found that CDKI-73 effectively blocks the growth of prostate cancer cells while sparing normal cells.
Continuation of renin-angiotensin system inhibitors before major noncardiac surgery was not associated with a higher rate of postoperative complications compared to discontinuation. The study aimed to investigate the impact of continued use of these medications on surgical outcomes.
Researchers have developed a novel nanoparticle drug-delivery system to activate an immune pathway in combination with tumor-targeting agents, showing promising results in treating pancreatic cancer. Eight out of nine mice tested experienced tumor improvements, including two complete responses.
A newly developed compound, MOD06051, targets neutrophils and reduces harmful inflammation in rat models. This approach differs from current treatments that may have broader immunosuppressive effects, offering a safer alternative.
Researchers developed a drug that enhances killer T cells' fighting power while reducing the toxicity of unmodified IL-2 treatments, overcoming inhibitory Tr1 cells and increasing immunotherapy's effectiveness. The study aims to personalize cancer immunotherapy for more patients.
An international team successfully realizes periodic oscillations and transportation for optical pulses using a synthetic temporal lattice. They observe the features of SBO collapse, including vanishing oscillation amplitude and flip of initial oscillation direction.
Researchers at Tokyo University of Science discovered a natural tyrosinase inhibitor from Corynebacterium tuberculostearicum that inhibits melanin synthesis and provides an alternative to toxic hydroquinone-based products. The compound, cyclo(L-Pro-L-Tyr), exhibits low toxicity and potential benefits for hyperpigmentation treatment.
A study published in Nature found that propofol can restore the function of mutated HCN1 ion channels, which are associated with certain types of epilepsy. The researchers suggest using propofol to treat these conditions or designing new compounds with similar effects but reduced side effects.
Researchers at Ohio State University are exploring the role of caspase 11 in SARS-CoV-2 infection, aiming to prevent inflammation and tissue injury. They will use human cell samples and experimental inhibitors to develop new treatment strategies for long COVID.
Researchers found that subretinal adeno-associated virus 8 injections trigger proinflammatory T-cell responses, but co-injection of immunodominant peptides can modulate the immune system. This study suggests a new approach to AAV gene therapy for retinal diseases.
Researchers explore various immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, as promising treatments for hepatocellular carcinoma. The review aims to overcome current limitations of targeted therapies by regulating the body's immune systems.
The study found that exercise increased PEDF levels in skeletal muscles and suppressed senescence markers in the lungs. PEDF also reduced senescence markers in multiple tissues and attenuated decline in respiratory function in pulmonary emphysema mouse model, suggesting its potential as a therapeutic agent for age-related diseases.
Researchers discovered that propofol, a commonly used anesthesia drug, induces unconsciousness by causing the brain to become increasingly unstable. This instability leads to chaotic brain activity, resulting in loss of consciousness. The study's findings could help develop better tools for monitoring patients during general anesthesia.
Researchers analyzed over 1.5 million patient records to find that metformin and SGLT-2 inhibitors lowered dementia and Alzheimer's disease risks compared to other antidiabetic drugs. The study suggests individualized treatment approaches considering patient-specific factors for optimal diabetes management.
Researchers found that regorafenib synergizes with TAS102 to inhibit cancer growth, angiogenesis, and microvessel density in preclinical models of colorectal and gastric cancers. The combination also suppresses ERK1/2 activation regardless of KRAS or BRAF mutational status.
A novel inhibitor HVH-2930 targeting heat shock protein 90 (HSP90) demonstrates efficacy against drug-resistant breast cancer cells. It selectively downregulates HER2 signaling, crucial for breast cancer progression, without triggering the heat shock response.
Researchers have made a breakthrough in understanding the GIP hormone's role in regulating insulin levels and weight loss. The study, involving over 500,000 individuals, found that inhibiting the GIP receptor may result in weight loss, while activating it without arresting its signal is crucial.
Essential oils have been shown to possess significant bioactive components with therapeutic potential, influencing various industries such as food, cosmetics, and pharmaceuticals. Their antioxidant, antimicrobial, and anti-inflammatory properties make them valuable in managing diseases like cancer, Alzheimer's, and diabetes.
A recent study suggests that inhibiting epigenetic control enzymes in immune cells, specifically HDAC1, improves anti-tumor immunity and tumor surveillance. This finding could lead to new therapeutic strategies in cancer immunotherapy.
The study reveals that the binding sites of USP28 and USP25 inhibitors are identical, leading to non-specific effects. Researchers now aim to develop precise inhibitors targeting either enzyme site to reduce side effects.
Research suggests that altered lipid signaling in brain cells contributes to mental disorders, with specific inhibitors showing promise in rebalancing this mechanism. The study found similar changes in both human patients and healthy relatives, as well as mice with genetic disorders, opening up new treatment opportunities.
A new study found that combining histone deacetylase inhibitors, poly (ADP ribose) polymerase inhibitors, and decitabine resulted in synergistic cytotoxicity in all cell lines tested. This combination impaired DNA repair pathways and altered epigenetic regulation of gene expression.
Researchers discuss Ibrutinib, a BTK inhibitor approved for chronic lymphocytic leukemia treatment, noting 20-25% of patients experience dose-limiting cardiovascular toxicities. A recent study identifies genetic biomarkers, such as KCNQ1 and GATA4, associated with cardiotoxic events, which may improve risk stratification.
A study led by Washington State University scientists found that inhibiting CDK7 could help prevent heart damage associated with doxorubicin, a commonly used cancer chemotherapy medication. The researchers also discovered that CDK7 inhibition enhances the medication's cancer-killing capability.
Researchers from Juntendo University discover that canagliflozin, an SGLT2 inhibitor, eliminates senescent cells and improves glucose metabolism in mice with dietary obesity. The study highlights the potential of this novel senolytic strategy for managing aging-related disorders.
Researchers developed a novel approach to block cancer cell growth by targeting specific proteins, reducing side effects and increasing treatment efficacy. The method uses antibody-peptide inhibitor conjugates, which deliver inhibitors specifically to cancer cells,
Scientists at Sanford Burnham Prebys and Vanderbilt University have identified phosphatidylinositol-5-phosphate 4-kinases (PI5P4Ks) as a key regulator of the hippo pathway, which is dysregulated in cancer. The study suggests that targeting PI5P4Ks may lead to new treatments for cancers with abnormal hippo signaling.
Researchers tested seven antibiotics in combination with various natural compounds, finding synergistic effects against multidrug-resistant bacteria. The study suggests combining antibiotics with plant extracts or phytochemicals could be a promising strategy to combat antimicrobial resistance.
Researchers found that matcha mouthwash significantly reduced levels of Porphyromonas gingivalis in saliva samples from people with periodontitis. Matcha's bactericidal activity against the pathogen was confirmed through lab experiments.
Researchers found that miR-377 reduces MYC mRNA levels, leading to increased Bax and PTEN expression and decreased CDK4. This results in induced apoptosis, inhibited proliferation, and arrested cell cycle in prostate cancer cells.
A team of POSTECH and ImmunoBiome has discovered a dietary-derived bacterial strain, IMB001, that induces nutritional immunity and boosts anti-tumor responses. The strain works by skewing tumor-infiltrating macrophages toward an inflammatory phenotype, leading to increased cell death of rapidly multiplying tumor cells.
A team of researchers led by Dr. Ahmed discovered that two FDA-approved antibiotics can induce heart regeneration in mammals, showing promise for treating heart failure. The study found that the antibiotics improved cardiac output and reduced fibrotic scar tissue, suggesting a potential new therapy.
Researchers found that SARS-CoV-2 spike protein interrupts p53-MDM2 interaction but does not bind with p53 protein in cancer cells. The study also shows that SARS-CoV-2 spike suppresses p53-dependent gene activation, leading to increased cell viability after chemotherapy exposure.
MD Anderson researchers presented studies on combination therapies for AML and lung cancer, tumor microbiomes in immunity, and improved HPV screening. Genetic markers predict extended survival with KRAS inhibitors and may identify patients who benefit from novel combinations.
Long-term treatment with methylene blue (MB) and mitoquinone (MitoQ) did not alter age-related bone loss in mice. Antioxidant interventions are insufficient to inhibit skeletal aging, suggesting alternative approaches may be needed.
Researchers at Tel Aviv University developed a novel therapeutic strategy using existing medications to inhibit bone metastasis in breast cancer patients. The combination of drugs improved survival rates and reduced bone metastases in animal models and human tissue samples.
Researchers discovered that MEIS2 plays a critical role in activating genes necessary for the formation of inhibitory projection neurons, vital for motion control and decision-making. A MEIS2 mutation found in patients with intellectual disability disrupts these processes.
Researchers found that chlorogenic acid enhances osteoblast proliferation and differentiation, while inhibiting RANKL-induced osteoclastogenesis. Administration of chlorogenic acid antagonizes ovariectomized-induced bone loss in rats.
Researchers unveil innovative strategies to overcome metabolic constraints in CAR-T cell therapy, aiming to boost its efficacy in treating solid tumors. Metabolic interventions targeting immunosuppressive metabolites, metabolite uptake, and mitochondrial metabolism are proposed to enhance anti-tumor activity.
A UNIGE team has identified the mechanism of action of PARP inhibitors, used to treat breast and ovarian cancer. By blocking one activity while preserving another, these inhibitors can maintain toxic effects on cancer cells while sparing healthy cells.
Researchers at St. Jude Children's Research Hospital have discovered that myeloid cell leukemia-1 (MCL-1) plays a critical role in regulating long-chain fatty acid oxidation in mitochondria, revealing new insights into its anti-apoptotic functions and potential therapeutic applications.
Researchers investigated the mechanism of 2′, 5′-Dihydroxyacetophenone (DHAP) in cytokine storm and found it inhibits inflammatory factors and increases Hdac1 protein stability, alleviating symptoms.
Scientists at St. Jude Children's Research Hospital found that ruxolitinib, a drug inhibiting both Janus Kinase 1 (JAK1) and JAK2, is a safe and potentially more effective therapy for Hemophagocytic lymphohistiocytosis (HLH), a rare and aggressive syndrome of hyperactive inflammation. The study showed that ruxolitinib increased surviva...
Researchers investigated combining Sacituzumab govitecan with platinum-based chemotherapeutics for triple-negative breast cancer, urinary bladder carcinoma, and small-cell lung carcinoma. The study showed additive to synergistic antitumor effects in vitro and in vivo, with improved outcomes in tumor-bearing animals.
A long non-coding RNA called lncREST has been identified as a crucial component of the stress response during DNA replication. Its absence leads to impaired stress signalling, resulting in severe DNA defects and cell death. The discovery opens up new avenues for developing anti-tumour therapies.
Researchers at Johns Hopkins Medicine have reported promising results from a clinical trial testing a novel immunotherapy combination to target advanced, potentially lethal skin cancers in kidney transplant patients. Two out of six patients experienced complete tumor regression after adding a second checkpoint inhibitor to the regimen.
Researchers found GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells, activating key pathways including ATM, AMPK, NFκB, and macroautophagy. The compound's unique multi-factorial mechanism suggests potential for treating mycosis fungoides.
A new strategy used by cancer cells to protect themselves from immune system attack has been identified, and a potential target for immunotherapy has been found. Blocking activin receptor 1C on CD4+ T cells may help prevent the accumulation of immune-suppressing Tregs in tumors and slow tumor growth.